{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:40:51Z","timestamp":1774917651572,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA050629"],"award-info":[{"award-number":["R01DA050629"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["1819-HQ-000036"],"award-info":[{"award-number":["1819-HQ-000036"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jsat.2021.108714","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T04:26:32Z","timestamp":1640665592000},"page":"108714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013\u201314"],"prefix":"10.1016","volume":"138","author":[{"given":"Emanuel","family":"Krebs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natt","family":"Hongdilokkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong E.","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T.","family":"Schnepel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Shigeoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.jsat.2021.108714_bb0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","article-title":"Stigma, discrimination and the health of illicit drug users","volume":"88","author":"Ahern","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.jsat.2021.108714_bb0015","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2105\/AJPH.2012.301168","article-title":"Offender diversion into substance use disorder treatment: The economic impact of California's proposition 36","volume":"103","author":"Anglin","year":"2013","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2021.108714_bb0020","series-title":"Mostly harmless econometrics: An empiricist's companion","author":"Angrist","year":"2008"},{"issue":"3","key":"10.1016\/j.jsat.2021.108714_bb0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12160-016-9772-1","article-title":"You can't always get what you want: The influence of choice on nocebo and placebo responding","volume":"50","author":"Bartley","year":"2016","journal-title":"Annals of Behavioral Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2005.05.010","article-title":"Cycling in and out of treatment; participation in methadone treatment in NSW, 1990\u20132002","volume":"81","author":"Bell","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108714_bb0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108714_bb0040","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/j.pain.0000000000001981","article-title":"Placebo 2.0: The impact of expectations on analgesic treatment outcome","volume":"161","author":"Bingel","year":"2020","journal-title":"Pain"},{"issue":"70","key":"10.1016\/j.jsat.2021.108714_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001244","article-title":"The effect of treatment expectation on drug efficacy: Imaging the analgesic benefit of the opioid remifentanil","volume":"3","author":"Bingel","year":"2011","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.jsat.2021.108714_bb0050","series-title":"Research 101 a manifesto for ethical research in the downtown eastside","author":"Boilevin","year":"2019"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.116793","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate","volume":"70","author":"Boulton","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.jsat.2021.108714_bb0060","author":"British Columbia Centre on Substance Use"},{"key":"10.1016\/j.jsat.2021.108714_bb0065","series-title":"Introduction of methadose","article-title":"BC PharmaCare newsletter","year":"2013"},{"key":"10.1016\/j.jsat.2021.108714_bb0070","series-title":"The British Columbia patient-centered care framework","year":"2015"},{"key":"10.1016\/j.jsat.2021.108714_bb9010","series-title":"PharmaNet","author":"British Columbia Ministry of Health","year":"2018"},{"key":"10.1016\/j.jsat.2021.108714_bb9000","series-title":"Medical Services Plan (MSP) Payment Information File","author":"British Columbia Ministry of Health","year":"2018"},{"key":"10.1016\/j.jsat.2021.108714_bb9030","series-title":"Discharge Abstract Database (Hospital Separations)","author":"British Columbia Ministry of Health","year":"2018"},{"key":"10.1016\/j.jsat.2021.108714_bb9050","series-title":"Vital Statistics Deaths","author":"British Columbia Vital Statistics Agency","year":"2018"},{"issue":"8","key":"10.1016\/j.jsat.2021.108714_bb0080","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"issue":"18","key":"10.1016\/j.jsat.2021.108714_bb0085","doi-asserted-by":"crossref","first-page":"E659","DOI":"10.1503\/cmaj.170363","article-title":"Guideline for opioid therapy and chronic noncancer pain","volume":"189","author":"Busse","year":"2017","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.jsat.2021.108714_bb0090","series-title":"\u201cNothing About Us Without US\u201d greater meaningful involvement of people who use illegal drugs: A public health, ethical, and human rights imperative","year":"2006"},{"key":"10.1016\/j.jsat.2021.108714_bb0095","series-title":"Policy guide. Methadone maintenance therapy. (Professional practice policy-66)","year":"2013"},{"key":"10.1016\/j.jsat.2021.108714_bb0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-pharmtox-010818-021542","article-title":"The placebo effect in pain therapies","volume":"59","author":"Colloca","year":"2019","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"6","key":"10.1016\/j.jsat.2021.108714_bb0105","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1056\/NEJMra1907805","article-title":"Placebo and nocebo effects","volume":"382","author":"Colloca","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2021.108714_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/YCO.0b013e328343803b","article-title":"Role of expectations in health","volume":"24","author":"Colloca","year":"2011","journal-title":"Current Opinion in Psychiatry"},{"issue":"7375","key":"10.1016\/j.jsat.2021.108714_bb0115","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bmj.325.7375.1263","article-title":"Systematic review of involving patients in the planning and development of health care","volume":"325","author":"Crawford","year":"2002","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jsat.2021.108714_bb0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment","volume":"78","author":"Crettol","year":"2005","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"20","key":"10.1016\/j.jsat.2021.108714_bb0125","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/jama.2017.4545","article-title":"Changing mindsets to enhance treatment effectiveness","volume":"317","author":"Crum","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108714_bb0130","series-title":"Democratizing health: Consumer groups in the policy process","author":"de Leeuw","year":"2011"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108714_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"22","key":"10.1016\/j.jsat.2021.108714_bb0140","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2014.16153","article-title":"Methods for evaluating changes in health care policy: The difference-in-differences approach","volume":"312","author":"Dimick","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jsat.2021.108714_bb0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tips.2011.12.001","article-title":"Utilizing placebo mechanisms for dose reduction in pharmacotherapy","volume":"33","author":"Doering","year":"2012","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archpsyc.55.1.89","article-title":"High interindividual variability of methadone enantiomer blood levels to dose ratios","volume":"55","author":"Eap","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0376-8716(00)00121-6","article-title":"Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment","volume":"61","author":"Eap","year":"2000","journal-title":"Drug and Alcohol Dependence"},{"issue":"14","key":"10.1016\/j.jsat.2021.108714_bb0160","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone","volume":"41","author":"Eap","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"issue":"3","key":"10.1016\/j.jsat.2021.108714_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0740-5472(99)00008-2","article-title":"Three oral formulations of methadone: A clinical and pharmacodynamic comparison","volume":"17","author":"Gourevitch","year":"1999","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108714_bb0170","series-title":"A guideline for the clinical management of opioid use disorder","year":"2017"},{"key":"10.1016\/j.jsat.2021.108714_bb0180","series-title":"Peer engagement best practices: A guide for health authorities and other providers","author":"Greer","year":"2017"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-018-5765-2","article-title":"Participant, peer and PEEP: Considerations and strategies for involving people who have used illicit substances as assistants and advisors in research","volume":"18","author":"Greer","year":"2018","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13011-016-0048-3","article-title":"Patient perspectives of methadone formulation change in British Columbia, Canada: Outcomes of a provincial survey","volume":"11","author":"Greer","year":"2016","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0195","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12889-016-3136-4","article-title":"Peer engagement in harm reduction strategies and services: A critical case study and evaluation framework from British Columbia, Canada","volume":"16","author":"Greer","year":"2016","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0200","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1152\/physrev.00033.2018","article-title":"Pavlovian conditioning of immunological and neuroendocrine functions","volume":"100","author":"Hadamitzky","year":"2020","journal-title":"Physiological Reviews"},{"issue":"5","key":"10.1016\/j.jsat.2021.108714_bb0205","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.drugpo.2006.12.018","article-title":"The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection","volume":"18","author":"Hopwood","year":"2007","journal-title":"The International Journal on Drug Policy"},{"issue":"12","key":"10.1016\/j.jsat.2021.108714_bb0210","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/add.15087","article-title":"Global opioid agonist treatment: A review of clinical practices by country","volume":"115","author":"Jin","year":"2020","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJMp1504023","article-title":"Placebo effects in medicine","volume":"373","author":"Kaptchuk","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2021.108714_bb0220","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0163-1047(81)90411-8","article-title":"Conditional hyperalgesia is elicited by environmental signals of morphine","volume":"32","author":"Krank","year":"1981","journal-title":"Behavioral and Neural Biology"},{"issue":"5","key":"10.1016\/j.jsat.2021.108714_bb0225","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.biopsych.2019.07.017","article-title":"Distorted cognitive processes in major depression: A predictive processing perspective","volume":"87","author":"Kube","year":"2020","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/j.jsat.2021.108714_bb0230","first-page":"85","article-title":"The stigmatization of problem drug users: A narrative literature review","volume":"20","author":"Lloyd","year":"2013","journal-title":"Drugs: Education, Prevention and Policy"},{"issue":"2","key":"10.1016\/j.jsat.2021.108714_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2021.108714_bb0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.socscimed.2015.04.008","article-title":"Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study","volume":"133","author":"McNeil","year":"2015","journal-title":"Social Science & Medicine"},{"key":"10.1016\/j.jsat.2021.108714_bb0245","series-title":"Crackdown Episode 2: Change intolerance","author":"Mullins","year":"2019"},{"issue":"2","key":"10.1016\/j.jsat.2021.108714_bb0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2524.2007.00739.x","article-title":"Barriers to accessing generic health and social care services: A qualitative study of injecting drug users","volume":"16","author":"Neale","year":"2008","journal-title":"Health and Social Care in the Community"},{"issue":"6","key":"10.1016\/j.jsat.2021.108714_bb0255","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3945","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen","year":"2016","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"6","key":"10.1016\/j.jsat.2021.108714_bb0260","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/aje\/kwp186","article-title":"Proportional hazards frailty models for recurrent methadone maintenance treatment","volume":"170","author":"Nosyk","year":"2009","journal-title":"American Journal of Epidemiology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108714_bb0270","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamainternmed.2018.7111","article-title":"Utilization of long-acting reversible contraceptives in the United States after vs before the 2016 US presidential election","volume":"179","author":"Pace","year":"2019","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108714_bb0275","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: Health services experiences among people who inject drugs","volume":"57","author":"Paquette","year":"2018","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2021.108714_bb0280","article-title":"Mortality among people with opioid use disorder during an opioid overdose public health emergency in British Columbia,Canada","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2021.108714_bb0285","series-title":"Peer engagement principles and best practices: A guide for BC health authorities and other providers","year":"2017"},{"issue":"9","key":"10.1016\/j.jsat.2021.108714_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036102","article-title":"Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: A population-based observational study protocol in British Columbia, Canada","volume":"10","author":"Piske","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.jsat.2021.108714_bb0295","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/add.14947","article-title":"The cascade of care for opioid use disorder: A retrospective study in British Columbia, Canada","volume":"115","author":"Piske","year":"2020","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.jsat.2021.108714_bb0300","first-page":"797","article-title":"From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia","volume":"66","author":"Raski","year":"2020","journal-title":"Canadian Family Physician"},{"issue":"3","key":"10.1016\/j.jsat.2021.108714_bb0305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-016-4466-8","article-title":"Learning to experience side effects after antidepressant intake\u2013Results from a randomized, controlled, double-blind study","volume":"234","author":"Rheker","year":"2017","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108714_bb0310","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/pr.114.009423","article-title":"Neuro-bio-behavioral mechanisms of placebo and nocebo responses: Implications for clinical trials and clinical practice","volume":"67","author":"Schedlowski","year":"2015","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.jsat.2021.108714_bb0315","series-title":"Psychoactive drugs","first-page":"115","article-title":"Pharmacological conditioning and drug effects","author":"Siegel","year":"1989"},{"issue":"4","key":"10.1016\/j.jsat.2021.108714_bb0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0740-5472(96)00099-2","article-title":"Change intolerance to shifts in methadone formulation: A preliminary investigation","volume":"13","author":"Silver","year":"1996","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108714_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2017.03.008","article-title":"Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis","volume":"45","author":"Soc\u00edas","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2021.108714_bb0330","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2021.108714_bb0335","series-title":"Stata statistical software: Release 15","author":"StataCorp","year":"2017"},{"key":"10.1016\/j.jsat.2021.108714_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4851","article-title":"Impact of supervision of methadone consumption on deaths related to methadone overdose (1993\u20132008): Analyses using OD4 index in England and Scotland","volume":"341","author":"Strang","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2021.108714_bb0345","series-title":"Medications for opioid use disorder: treatment improvement protocol (TIP) series 63. HHS Publication No.(SMA)","year":"2018"},{"issue":"1","key":"10.1016\/j.jsat.2021.108714_bb0350","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric metabolic interactions and stereoselective human methadone metabolism","volume":"321","author":"Totah","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2021.108714_bb0355","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0165-0327(97)00125-0","article-title":"Medication side effects in anxious patients: Negative placebo responses?","volume":"47","author":"Uhlenhuth","year":"1998","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.jsat.2021.108714_bb0365","series-title":"Econometric analysis of cross section and panel data","author":"Wooldridge","year":"2010"},{"issue":"8","key":"10.1016\/j.jsat.2021.108714_bb0370","first-page":"336","article-title":"Opioid prescribing patterns in British Columbia from 2013 to 2017: A population-based study","volume":"62","author":"Yefet","year":"2021","journal-title":"BC Medical Journal"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221004402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221004402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:27Z","timestamp":1760039787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221004402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":73,"alternative-id":["S0740547221004402"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108714","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013\u201314","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108714"}}